aibioLIANY LianBio
LianBio (LIANY) news
LianBio is a public biotech or pharmaceutical company listed on OTC under the ticker LIANY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest LianBio news
We have not published a story on LianBio yet. When there is news, it will appear here.
LianBio annual financials
| Line | FY2022 | FY2021 |
|---|---|---|
| Research and development | $59.8 million | $158.7 million |
| Net income (loss) | -$110.3 million | -$196.3 million |
| Cash from operations | -$99.2 million | -$164.0 million |
| Cash and equivalents | $79.2 million | $228.2 million |
| Short-term investments | $223.1 million | $155.1 million |
Questions about LianBio
What is the ticker symbol of LianBio?
LianBio trades under the ticker LIANY on OTC.
Where is LianBio listed?
LianBio is listed on OTC.
What is the SEC CIK of LianBio?
The SEC Central Index Key (CIK) for LianBio is 1831283. Its filings are on SEC EDGAR.
How many shares does LianBio have outstanding?
108,062,638 shares as of 2023-11-09, per the cover page of its 10-Q filed 2023-11-13.
Which country or territory is LianBio listed under?
Our directory records LianBio under United States.
What does LianBio do?
Our directory classifies LianBio as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of LianBio?
The ISIN recorded for LianBio is US53000N1081.
Does aibio.space cover LianBio?
aibio.space lists LianBio among 2,820 public biotech companies and publishes its news here as stories appear.
Where is LianBio incorporated?
SEC records list its state or country of incorporation as E9.
Is LianBio profitable?
LianBio reported a net loss of $110.3 million for the fiscal year ended Dec 31, 2022, and used $99.2 million of cash in operations, per its annual report to the SEC.
How much does LianBio spend on research and development?
$59.8 million in the fiscal year ended Dec 31, 2022, per its annual report.
How much cash does LianBio have?
$252.2 million in cash and short-term investments at Sep 30, 2023, per its 10-Q.
Is LianBio a smaller reporting company?
SEC records list LianBio's filer category as: <br>Emerging growth company.
Where is LianBio headquartered?
SEC records list its business address as 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON, NJ, 08540.
When does LianBio's fiscal year end?
LianBio's fiscal year ends on December 31, per SEC records.
Investor discussion: LianBio
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- LianBio
- CIK
- 1831283
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- LIANY (OTC)
- State or country of incorporation
- E9
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON, NJ, 08540
- Phone
- (609) 486-2308
- Shares outstanding
- 108,062,638 as of 2023-11-09 (10-Q filed 2023-11-13)
Recent filings
Listing details
- Company
- LianBio
- Ticker
- LIANY
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US53000N1081
- Last quote in directory
- 2026-10-20
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction